Cargando…
DCLK1 autoinhibition and activation in tumorigenesis
Doublecortin-like kinase 1 (DCLK1) is upregulated in many tumors and is a marker for tumor stem cells. Accumulating evidence suggests DCLK1 constitutes a promising drug target for cancer therapy. However, the regulation of DCLK1 kinase activity is poorly understood, particularly the function of its...
Autores principales: | Cheng, Linna, Yang, Zejing, Guo, Wenhao, Wu, Chengyong, Liang, Shufang, Tong, Aiping, Cao, Zhongwei, Thorne, Rick F., Yang, Sheng-Yong, Yu, Yamei, Chen, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686072/ https://www.ncbi.nlm.nih.gov/pubmed/34977835 http://dx.doi.org/10.1016/j.xinn.2021.100191 |
Ejemplares similares
-
Molecular Mechanism of Mutational Disruption of DCLK1 Autoinhibition Provides a Rationale for Inhibitor Screening
por: Chen, Weizhi, et al.
Publicado: (2023) -
Structure-Guided Prediction of the Functional Impact of DCLK1 Mutations on Tumorigenesis
por: Carli, Annalisa L. E., et al.
Publicado: (2023) -
Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity
por: Ding, Ling, et al.
Publicado: (2021) -
DCLK1 immunoreactivity in colorectal neoplasia
por: Gagliardi, Giuseppe, et al.
Publicado: (2012) -
XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression
por: Yang, Wei-Qiang, et al.
Publicado: (2021)